TORONTO and HOUSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a scientific stage immuno-oncology firm, at present introduced the voting outcomes from the Company’s annual assembly of shareholders held at present, September 21, 2022 (the “Meeting”).
Medicenna is happy to announce that each one of the nominees listed within the administration proxy round dated August 2, 2022 have been elected as administrators. Each of the administrators was elected with higher than 97% of the votes forged by shareholders current on the Meeting or represented by proxy. The outcomes of the vote are detailed under:
|Nominee||Votes For||% of
|% of Votes
|Dr. Fahar Merchant||24,859,038||97.878||538,956||2.122|
|Mr. Albert Beraldo||24,877,225||97.950||520,768||2.050|
|Ms. Karen Dawes||24,902,175||98.048||495,818||1.952|
|Dr. John (Jack) Geltosky||24,728,697||97.365||669,296||2.635|
|Ms. Rosemina Merchant||24,653,185||97.067||744,808||2.933|
|Dr. Chandrakant Panchal||24,820,996||97.728||576,997||2.272|
|Dr. John Sampson||24,840,678||97.806||557,315||2.194|
Medicenna shareholders additionally voted to nominate PricewaterhouseCoopers LLP as auditor of the Company.
A complete of 57.468% of the issued and excellent widespread shares of the Company have been represented in particular person and by proxy on the Meeting.
Medicenna is a scientific stage immunotherapy firm targeted on the event of novel, extremely selective variations of IL-2, IL-4 and IL-13 Superkines and first at school Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding with out CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating most cancers killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bipurposeful SuperOkayine ImmunoTherapies) is designed to reinforce the power of Superkines to deal with immunologically “cold” tumors. Medicenna’s IL-4 Empowered Superkine, MDNA55, has been studied in 5 scientific trials together with a Phase 2b trial for recurrent GBM, the most typical and uniformly deadly type of mind most cancers. MDNA55 has obtained Fast-Track and Orphan Drug standing from the FDA and FDA/EMA, respectively.
For additional details about the Company please contact:
Elizabeth Williams, Chief Financial Officer, 416-648-5555, email@example.com
For extra investor info, please contact:
Dan Ferry, Managing Director, LifeSci Advisors, 617-430-7576, firstname.lastname@example.org